Rigel Pharmaceuticals, Incorporated

Atex Technologies, Inc.

David Carroll

Rajinder Paul Singh

Hui Li

Ankush Argade

Somasekhar Bhamidipati

Sambaiah Thota

Kin Tso

Vanessa Taylor

Jeffrey Clough

Arvinder Sran

Robin Cooper

Holger Keim

Donald G Payan

Simon Shaw

Dane A Goff

Brian Wong

Catherine Sylvain

Yasumichi Hitoshi

Vadim Markovtsov

Esteban Masuda

John McLaughlin

Susan Catalano

John Yudhistir Ramphal

Andy Atuegbu

Mark Markovtsov

Alexander B Rossi

Brian L McMurray

Taisei Kinoshita

Sarkiz D Issakani

Mark Wesley Jessup

Jianing Huang

Tarikere Gururaja

Vadim M V Markovtsov

Tim Warner

Morgan Gwaltney

Gary Webb Broussard, Jr

Lyuben Tsvetkov

Hitoshi Yasumichi

Avinder Sran

Sarkiz Issakani

Dane Goff

Argade Ankush

Singh Rajinder

Brian Mcmurray

Webb Broussard

Mark Jessup

Stephanie Norris

Improved methods, designs and/or systems for incorporating markings and/or other visual and/or tactilely identifiable indicia on woven, knitted, nonwoven, braided and/or felted textiles used for medical textile implants and prostheses, including medical graft prostheses that would not affect the overall mechanical performance of the textile.

Indicator marking technology for textiles

The invention encompasses compounds having formula I-V and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, may be therapeutically useful.

Compositions and methods for inhibition of the JAK pathway

The invention encompasses compounds having formula I and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, particularly JAK3, are therapeutically useful.

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lupus erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

Methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds

Disclosed are substituted pyridine compounds as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure wherein E, J, T, the ring system denoted by 'B', T, R, R, w and x are as described herein. In certain embodiments, a compound disclosed herein activates the AMPK pathway, and can be used to treat metabolism-related disorders and conditions.

AMPK-activating heterocyclic compounds and methods for using the same

Disclosed are sulfonamidoquinoline compounds, as well as pharmaceutical compositions and methods of use. One embodiment is a compound having the structure and pharmaceutically acceptable salts, prodrugs and N-oxides thereof (and solvates and hydrates thereof), wherein R, R, Rand Rare as described herein. In certain embodiments, a compound disclosed herein inhibits ubiquitination, and can be used to treat disease by blocking the degradation of tumor suppressors.

Ubiquitination inhibitors

The present invention provides methods of treating or preventing autoimmune diseases with 2,4-pyrimidinediamine compounds, as well as methods of treating, preventing or ameliorating symptoms associated with such diseases. Specific examples of autoimmune diseases that can be treated or prevented with the compounds include rheumatoid arthritis and/or its associated symptoms, systemic lups erythematosis and/or its associated symptoms and multiple sclerosis and/or its associated symptoms.

The present disclosure provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferate diseases such as tumorigenic cancers.

Cycloalkyl substituted pyrimidinediamine compounds and their uses

The present invention provides 2,4-pyrimidinediamine compounds having antiproliferative activity, compositions comprising the compounds and methods of using the compounds to inhibit cellular proliferation and to treat proliferative diseases such as tumorigenic cancers.

2,4-pyrimidinediamine compounds and uses as anti-proliferative agents

Growing community of inventors

San Francisco, CA, United States of America

David Carroll